SEC Tracker
Get the app
AVTX · XBRL financial data

Avalo Therapeutics financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (AVTX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers236571*00249192*——059*——
Cost of goods and services sold247(221)*(80)343(714)——0————
Selling, general and administrative2,4902,676*——————————
General and administrative2,4902,676*3,1934,5284,2865,233*5,5465,2425,5776,534*6,8548,099
Operating income (loss)(3,750)(7,658)*(32,767)(9,575)(12,861)(13,311)*(14,669)(19,316)(19,198)(19,742)*(20,901)(31,517)
Other income (expense)(17)0*00(5)0*—(5)(3)———
Income tax expense (benefit)8(9)*77(14)114*81611130*1218
Net income (loss)(5,228)(8,168)*(121,290)98,46323,037(35,339)*(13,149)(20,765)(30,625)(13,720)*(19,630)(36,358)
Earnings per share, basic‡ USD per share(26.19)—(141.00)4.210.98—(1.25)(1.92)(2.19)—(0.98)(0.83)
Earnings per share, diluted‡ USD per share(26.19)—(141.00)(14.07)(2.83)—(1.25)(1.92)(2.19)—(0.98)(0.83)
Weighted average shares, basic‡ thousands of shares196—8591,0345,546—10,51510,83014,000—20,10743,602
Weighted average shares, diluted‡ thousands of shares196—8597,65310,784—10,51510,83014,000—20,10743,602
  • ‡ Per-share figures and share counts are adjusted for the 1-for-238.0952380952381 stock split (December 2023); filings made before it reported them unadjusted.
  • † Share count changed about 10x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (AVTX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents10,1807,415110,17793,42681,858134,546125,04642,29026,96315,85824,98885,382
Short-term investments—————0—70,97284,65482,47857,005314,894
Inventory00——————————
Prepaid and other current assets9408439972,4353,2513,7141,8331,9032,1396,9136,6857,607
Total current assets12,6598,395111,21395,89486,148138,890126,941115,185113,846105,28688,825407,932
Right-of-use asset1,3931,3291,2801,2111,139741615487402336268198
Goodwill14,40910,50210,50210,50210,50210,50210,50210,50210,50210,50210,50210,502
Total assets29,27020,993123,728108,30798,455150,732138,523126,583125,100116,45899,885490,783
Accounts payable7894469166541,8112836812,3664741373563,347
Total current liabilities6,0054,618215,70096,39760,6746,9605,6159,2597,97212,94011,59921,130
Lease liability, non-current1,4561,3661,2811,1831,0833502751971173500
Total liabilities14,57513,689224,813110,45875,72117,70015,90822,00933,55333,40931,56542,123
Accumulated deficit(326,966)(335,134)(456,424)(357,961)(334,924)(370,263)(383,412)(404,177)(434,802)(448,522)(468,152)(504,510)
Total stockholders' equity14,6957,304(112,542)(13,608)21,076133,032122,615104,57491,54783,04968,320448,660
Total liabilities and equity29,27020,993123,728108,30798,455150,732138,523126,583125,100116,45899,885490,783
Common shares outstanding (cover page)‡ thousands of shares8081,0341,0341,03410,39410,67210,82813,15218,13422,78852,56653,630
  • ‡ Per-share figures and share counts are adjusted for the 1-for-238.0952380952381 stock split (December 2023); filings made before it reported them unadjusted.
  • † Share count changed about 10x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (AVTX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024†Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(5,228)(8,168)*(121,290)98,46323,037(35,339)*(13,149)(20,765)(30,625)(13,720)*(19,630)(36,358)
Stock-based compensation953*776*629471*1,848*2,904*3,2412,718*3,154*4,508*3,5755,305*
Depreciation and amortization41*43*3433*34*68*135134*59*16*1717*
Net cash from operating activities(6,836)*(2,766)*(6,202)(16,283)*(11,527)*(15,044)*(9,457)(11,390)*(16,365)*(14,246)*(17,691)(19,988)*
Net cash from investing activities0*0*3560*0*0*0(70,860)*(13,261)*2,401*25,505(329,925)*
Proceeds from issuing common stock25,939*13,730*——0*0*———year only——
Net cash from financing activities10,695*1*108,612(472)*0*67,709*0(469)*14,369*687*1,399410,209*
Net change in cash3,859*(2,765)*102,766(16,755)*(11,527)*52,665*(9,457)(82,719)*(15,257)*(11,158)*9,21360,296*
  • † Share count changed about 10x in the period ending 2024-09-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Avalo Therapeutics85,382not reported(19,988)*53.6M20.0 quarters 10-QJun 30, 2026
Cue Biopharma17,3927,877(29,004)*7.3M0.6 quarters 10-QJun 30, 2026
Fitlife Brands1,089not reported3,635*9.4M— 10-QJun 30, 2026
Immucell8,8607,1863,019*9.1M— 10-QJun 30, 2026
iBio56,3950*(6,228)*64.3M14.1 quarters 10-KJun 30, 2026
Sutro Biopharma54,3359,839(38,290)*16.6M4.3 quarters 10-QJun 30, 2026
PDS Biotechnology5,596not reported(2,793)*56.0M2.0 quarters 10-QJun 30, 2026
Precision Biosciences81,6980(15,132)*27.9M6.1 quarters 10-QSep 30, 2026
Medicinova25,416458(1,920)*49.2M13.2 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.